CSL (ASX:CSL) said it is continuing to assess the broader impact of the newly imposed US tariffs and will monitor further announcements by the US Government, according to a Thursday Australian bourse filing.
The company noted that, currently, pharmaceutical products are not subject to the reciprocal tariffs.
The company intends to work with the US administration to ensure American patients retain access to its medicines, the filing added.